Currently, GenAns Biotech is conducting investigator-initiated trials for several gene therapies, including GA001 for ...

CGT Global, a leading biotechnology company driving the development and delivery of innovative cell and gene therapies, today ...

Sarepta Therapeutics (SRPT) stock in focus as report says company hired a Trump-linked lobbying firm after deaths linked to ...

A 26-year-old Downriver man seen at Children’s Hospital of Michigan in Detroit since infancy for a rare bleeding disorder in ...

The FDA's approval of the first CRISPR-Cas9–based gene therapy marked a major milestone in biomedicine, validating genome ...

Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.

India has over 180 children with Hunter Syndrome, but many people are not even aware of this genetic disorder which mostly ...

Enrollment Complete in Cohorts 1 and 2 of MyPEAK™-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB ...

Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs -- APOE program added to ...

Discover insights from MaxCyte's Q2 2025 earnings call, including revised revenue guidance, headwinds impact, and strategies for growth in the cell ...

Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials. The Danish pharma said that the Phase II trial of coramitug (PRX004), an mAb ...

Q2 2025 Earnings Call Transcript August 6, 2025 Charles River Laboratories International, Inc. misses on earnings ...